QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ANIP

QT79ANI Pharmaceuticals, Inc.
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA
Latest market price
79.49
-1.03-1.28%
OverviewShort InterestFilings
ANIPQT79ANI Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
79.49-1.28%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96TEVA-3.32%$31.48VTRS-2.29%$15.37ELAN+3.55%$24.22RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86
Snapshot
Index-P/E18.78EPS (ttm)
3.94
Insider Own24.24%
Shs Outstand22.75M
Perf Week-2.65%
Market Cap1.83BForward P/E7.32EPS next Y10.86Insider Trans-0.53%Shs Float-Perf Month-1.03%
Enterprise Value1.85BPEG0.01EPS next Q2.01Inst Own-Short Float-Perf Quarter6.24%
Income97.39MP/S1.98EPS this Y137.13%Inst Trans-Short Ratio-Perf Half Y-1.99%
Sales923.73MP/B2.99EPS next Y16.19%ROA6.31%Short Interest-Perf YTD0.70%
Book/sh24.70P/C8.07EPS next 5Y12.95%ROE17.32%52W High99.50 -20.11%Perf Year25.48%
Cash/sh13.67P/FCF11.42EPS past 3/5Y-ROIC8.17%52W Low62.61 26.96%Perf 3Y-
Dividend Est.-EV/EBITDA7.87Sales past 3/5Y40.85% 33.53%Gross Margin65.94%Volatility1.86% 1.96%Perf 5Y-
Dividend TTM-EV/Sales2.00EPS Y/Y TTM890.38%Oper. Margin13.38%ATR (14)2.51Perf 10Y-
Dividend Ex-Date-Quick Ratio2.52Sales Y/Y TTM50.33%Profit Margin9.71%RSI (14)47.24Recom2.30
Dividend Gr. 3/5Y-Current Ratio3.12EPS Q/Q20.59%SMA20-1.07%Beta0.56Target Price124.00
Payout0.84%Debt/Eq0.58Sales Q/Q20.30%SMA50-0.81%Rel Volume1.02Prev Close80.52
Employees897LT Debt/Eq0.57EarningsAug 14SMA200-4.30%Avg Volume343.88KPrice79.49
IPO DateMay 05, 2000Option/ShortYes / YesEPS/Sales Surpr.60.16% 13.94%Net Debt/EBITDA0.07Volume351,433Change-1.28%
Analyst Ratings
DateActionAnalystRatingTarget
Jan-16-26ReiteratedGuggenheimBuy$114 → $124
Oct-09-25ReiteratedTruist Financial$77 → $90
Sep-17-25ReiteratedH.C. Wainwright$93 → $121
Sep-08-25ReiteratedGuggenheimBuy$86 → $114
Aug-08-25ReiteratedPiper Sandler$80 → $94
Mar-05-25ReiteratedGuggenheimBuy$86
Sep-18-24ReiteratedRaymond JamesOutperform$48 → $83
Sep-11-24ReiteratedTruist Financial$60
Sep-11-24DowngradeTruist SecuritiesBuy → Hold
Jun-26-24ReiteratedH.C. Wainwright$87 → $94
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue923883614
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A316433250
Gross Profit610451364
Selling, General and Administrative Excl. Other316318250
Research and Development525245
Other Operating Expense117-169
Operating Income124811
Interest Expense322018
Unusual Expense
———
Non-Operating Income (Expense)-22-355
Net Income Before Taxes11696-22
Income Taxes2417-4
Consolidated Net Income8978-19
Net Income From Continuing Operations9278-19
Net Income8978-19
EPS (Recurring)4.113.50-1.04
EPS (Basic, Before Extraordinaries)4.113.50-1.04
EPS (Diluted)3.943.32-1.04
EBITDA23420763
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio20.1823.78—
Price To Sales Ratio1.811.79—
Gross Margin66.0951.0859.28
Operating Margin13.439.170.16
Net Margin9.648.83-3.09
Shares Outstanding212019
Market Capitalization1,6691,579—
Operating Lease Expense
———
Insider Trading Volume
$83.90$74.88$65.86$56.84$47.82● Close Price0.00M8.91M17.82M26.73M35.64MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Jun 12 '26Sale82.0350041,01577,890Jun 15 12:00 AM
HAUGHEY THOMASDirectorJun 08 '26Sale80.882,000161,76038,878Jun 10 12:00 AM
CAREY STEPHEN P.SVP & CFOJun 05 '26Option Exercise49.516,624327,954183,705Jun 09 12:00 AM
CAREY STEPHEN P.SVP & CFOJun 05 '26Sale80.003,312264,960180,393Jun 09 12:00 AM
Walsh Patrick DDirectorMay 13 '26Sale80.6310,000806,30038,432May 13 12:00 AM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.May 13 '26Sale78.1650039,08078,390May 13 12:00 AM
Gutwerg OriSVP, GENERICSMay 12 '26Sale79.502,772220,37478,696May 13 12:00 AM
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDSMay 12 '26Sale79.2145936,35738,271May 13 12:00 AM
Walsh Patrick DDirectorMay 11 '26Sale80.753,973320,82048,432May 13 12:00 AM
Lalwani NikhilPRESIDENT & CEOMay 11 '26Sale77.5755,0004,266,350349,889May 13 12:00 AM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Apr 13 '26Sale77.9550038,97578,890Apr 13 12:00 AM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Mar 13 '26Sale72.6250036,31079,390Mar 13 12:00 AM
Mutz ChristopherHEAD OF RARE DISEASEMar 13 '26Sale71.643,162226,52691,309Mar 13 12:00 AM
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDSMar 11 '26Sale74.914,772357,47138,730Mar 13 12:00 AM
Davis KristaSVP, CHIEF HR OFFICERMar 09 '26Sale74.135,087377,09951,946Mar 10 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR